Thymosin Alpha-1 Mechanism of Action: Full Pathway Explained
HealthRX.com
How thymosin alpha-1 is thought to act, and what is unknown
See the public record for Thymalfasin
At a glance
- What it is / 28-amino-acid peptide first isolated from thymosin fraction 5, a thymus extract [3]
- Described mechanism / immune modulator that augments T-cell function [1]
- Mechanism detail / pleiotropic, difficult to unravel [2]
- Peak and half-life / peak about 0.7 to 2 hours, half-life about 1.8 to 2.6 hours [3]
- US status / not FDA-approved; orphan designations are not approvals [3]
What the pharmacology describes
Thymosin alpha-1 is a 28-amino-acid peptide with an acetylated N-terminal end, first isolated from thymosin fraction 5, a thymus extract; thymalfasin is the synthetic version with the same sequence [3].
Its own literature describes it as an immune modulator that augments T-cell function, and says it may affect thymocytes by stimulating their differentiation or by converting them to active T cells [1]. A 2007 review of its pharmaceutical development noted the pleiotropic nature of the mechanism of action and the resulting difficulty in unravelling the pharmacological effects [2].
After subcutaneous injection in healthy volunteers, peak levels came at about 0.7 to 2 hours and the half-life was about 1.8 to 2.6 hours, with no accumulation after five daily doses [3][1].
What people on Reddit report
Two people in a thread about thymosin alpha-1 disagree about whether it raises or lowers T-cell activity, and why that matters for autoimmune risk.
You don't want to jack up T cell activity if T cell activity is already problematic.Read the source discussion
You're saying TA1 jacks up T Cell activity but I thought it decreases it? Thus lowering autoimmunityRead the source discussion
Questions worth asking
Thymosin alpha-1 in 3D: the measured peptide
All 28 amino acids of thymosin alpha-1 with the acetyl cap on its first amino acid, as measured in solution. Turn it to follow the chain from one end to the other.
- Carbon
- Oxygen
- Nitrogen
Formula, weight and what this structure shows
| Molecular formula | C129H215N33O55 |
|---|---|
| Molecular weight | 3108.3 g/mol |
| Atoms shown | 217 (Carbon 129, Oxygen 55, Nitrogen 33). Hydrogen atoms are left out. |
| Bonds shown | 216 |
| How the shape was found | Solution NMR of thymosin alpha-1 on its own. This is the first of the 21 models in the entry; NMR entries hold several because a peptide this size moves in solution. |
What was measured in people
A 1991 placebo-controlled pilot gave seven of 12 people with chronic hepatitis B thymosin fraction 5 or thymosin alpha-1 and five placebo twice weekly for six months. Response to thymosin was associated with rises in peripheral blood lymphocyte, CD3 and CD4 counts and in in vitro interferon-gamma production, and HBV DNA cleared in six of seven treated patients versus one of five on placebo (P < 0.04) [4].
A 2026 Cochrane review pooled 10 randomised trials in 1,349 adults published between 1991 and 2018. It reported possible lower all-cause mortality (risk ratio 0.53, 95% CI 0.29 to 0.96; 3 trials, 907 people) at very low certainty and little to no effect on quality of life or liver histology; the reviewers said they were not sure thymosin alpha-1 helps [5].
What the label says and what has been reported
The Italian Zadaxin label covers 1.6 mg given subcutaneously or intramuscularly twice weekly for four weeks starting at the first vaccination, repeated from week 8 to week 12 at the second vaccination. That label says it is not for children, is contraindicated in pregnancy and breastfeeding, and calls for caution in people with allergies or autoimmune disease and with other immune-modulating drugs [3]. It is not a US label; there is no FDA-approved thymosin alpha-1 product [3].
FDA's search of its adverse-event database on April 22, 2024 found zero reports for thymosin alpha-1 [3]. In the hepatitis B trials, the Cochrane review found possibly fewer serious adverse events than with the comparison treatments (risk ratio 0.72, 95% CI 0.53 to 0.99; 5 trials, 1,056 people; low-certainty evidence) [5].
Check what you know
Question 1 of 3
Score: 0 right, 0 of 3 answered
Frequently asked questions
Is thymosin alpha-1 FDA approved?
Is it the same as thymosin beta-4?
How long does it stay in the body?
References
Show all 7 referencesHide references
- Ancell CD, Phipps J, Young L. Thymosin alpha-1. Am J Health Syst Pharm. 2001;58(10):879-85; quiz 886-8.
- Tuthill C. Issues in pharmaceutical development of thymosin alpha1 from preclinical studies through marketing. Ann N Y Acad Sci. 2007;1112:351-6.
- U.S. Food and Drug Administration.
- Mutchnick MG, Appelman HD, Chung HT, Aragona E, Gupta TP, Cummings GD, et al. Thymosin treatment of chronic hepatitis B: a placebo-controlled pilot trial. Hepatology. 1991;14(3):409-15.
- Naing C, Ni H, Aung HH, Aye SN, Nikolova D, Poovorawan Y, et al. Thymosin-ɑ1 for people with chronic hepatitis B. Cochrane Database Syst Rev. 2026;9(9):CD014610.
- World Anti-Doping Agency.
- Reddit participants. Thymosin Alpha 1 (r/smallfiberneuropathy). Accessed 2026-11-11.